

COLLABORATIVE DATASPACE



LabKey User Conference

Drienna Holman, SCHARP/FHCRC

Britt Piehler, LabKey Software

October 23, 2014

Collaborative DataSpace (CDS) Program Overview

- Problem Statement
- Program Components
- Application Walk-through
- Considerations

Future of CDS

Problem Statement

nature medicine

VOLUME 16 NUMBER 9 SEPTEMBER 2010
www.nature.com/naturemedicine

COMMENTARY

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

The Council of the Global HIV Vaccine Enterprise

An important moment in HIV research

HIV/AIDS remains one of humanity's greatest challenges. Since 1981, it has claimed over 25 million lives and is currently responsible for over 23 million new infections worldwide each year. Although progress has been made in preventing new HIV infections and in providing increased access to antiretroviral therapy, the number of people living with HIV—now over 33 million—continues to grow. Currently, only two out of five people who need treatment receive it, and even those who do not have a universal goal, the modest level of availability of some antiretroviral drugs is declining. Wherever the need for more effective prevention strategies, vaccines are the primary public health intervention for dozens of infectious diseases worldwide; they are easy to administer and yield lasting effects. As one of the most powerful tools for preventing infection, effective eradicating disease, a safe, effective, accessible HIV vaccine—and one of science's greatest challenges—has an extraordinary potential to reduce the burden of HIV and to improve the health and well-being of billions of people. The unique properties of the immune system, the ability to establish long-term immunity, and the ability to learn and adapt to new challenges for vaccination present both opportunities and challenges for vaccine development.

Nonetheless, although HIV vaccine research has made significant progress in the past few years, the most visible achievements of the program are yet to come. There is a need for a new strategic approach, one that combines the strengths of the field and creates a path forward for the future. This is the mission of the Global HIV Vaccine Enterprise, a new organization that brings together the world's leading experts in HIV vaccine research to address the challenges of developing an effective HIV vaccine.

COMMENTARY

Progress in other areas of biomedical research, including the development of safe and effective pharmaceuticals, has been rapid and transformative. This progress is being driven by a combination of factors, including the use of high-throughput screening, the application of big data, and the use of computational biology. These advances are providing new insights into the mechanisms of disease and the development of new drugs. In the case of HIV, these advances are providing new insights into the mechanisms of infection and the development of new vaccines. The Global HIV Vaccine Enterprise is a new organization that brings together the world's leading experts in HIV vaccine research to address the challenges of developing an effective HIV vaccine. The Enterprise is committed to accelerating the development of an HIV vaccine that is safe, effective, and accessible to all who need it. The Enterprise is also committed to building a strong and sustainable global vaccine research and development infrastructure. The Enterprise is a global organization that brings together the world's leading experts in HIV vaccine research to address the challenges of developing an effective HIV vaccine. The Enterprise is committed to accelerating the development of an HIV vaccine that is safe, effective, and accessible to all who need it. The Enterprise is also committed to building a strong and sustainable global vaccine research and development infrastructure.

COMMENTARY

The Global HIV Vaccine Enterprise is a new organization that brings together the world's leading experts in HIV vaccine research to address the challenges of developing an effective HIV vaccine. The Enterprise is committed to accelerating the development of an HIV vaccine that is safe, effective, and accessible to all who need it. The Enterprise is also committed to building a strong and sustainable global vaccine research and development infrastructure. The Enterprise is a global organization that brings together the world's leading experts in HIV vaccine research to address the challenges of developing an effective HIV vaccine. The Enterprise is committed to accelerating the development of an HIV vaccine that is safe, effective, and accessible to all who need it. The Enterprise is also committed to building a strong and sustainable global vaccine research and development infrastructure. The Enterprise is a global organization that brings together the world's leading experts in HIV vaccine research to address the challenges of developing an effective HIV vaccine. The Enterprise is committed to accelerating the development of an HIV vaccine that is safe, effective, and accessible to all who need it. The Enterprise is also committed to building a strong and sustainable global vaccine research and development infrastructure.

“Dramatic shift in the culture and practice of sharing research data”



Current process



The Collaborative DataSpace Program

CDS Program



Data

Content-rich, annotated catalog
of integrated study data and
metadata



Services

Outreach, analysis and support
services



Governance

Promotes engagement and data
consistency across networks



Application

Web-based app combines CDS
data compendium and user
services and applies data
security model

What CDS is (and what it isn't)

CDS helps researchers:

- Discover basic facts and learn what data exist
- Perform quick, low-cost tests of ideas
- Compare data across studies and assay types
- Communicate findings

CDS is not:

- Source for statistical proof
- Deep analysis environment
- Source for raw lab data
- Repository of “datasets”

The Components of CDS




Application Walk-through

Welcome to the HIV Vaccine Collaborative Dataspace.

6 studies connected together combining 20,501 data points.

The Global HIV Vaccine Enterprise called for a dramatic change in the culture and practice of sharing research data, and UNAIDS demanded, "faster, smarter, better" programs. Solutions will come from collective efforts and strong community interaction.

The HIV Vaccine Data Connector is the place to find potential relationships between data sets that were previously difficult to compare due to access restrictions and problems of data alignment.



I agree to protect restricted data, credit others, and obtain official approval to publish.

I have read, understood, and agree to the terms of use available below.

Email address:

Password:

Remember my email address
[Forgot your password?](#)

[sign in](#)

To access and view data in this site you must agree to the Terms of Use for HIV Collaborative DataSpace, which are available for review by clicking the link below. Please read these terms carefully. By accessing this site you agree to be bound by these terms. These terms are subject to change. Any changes will be incorporated into the terms posted to this site from time to time. If you do not agree with these terms, please do not access the site. If you are not an authorized user of this site you are hereby notified that any access or use of the information herein is strictly prohibited.

[Terms of Use of the HIV Collaborative DataSpace](#)

Welcome to the HIV Vaccine Collaborative Dataspace.
6 studies connected together combining
20,501 data points.

[About the Collaborative Dataspace...](#)

Home

- Learn about studies, assays, ...
- Find subjects
- Plot data
- View data grid

My saved groups and plots

- Immune Response / BMI - All
- Immune Response / BMI - LBKY001
- Immune Response / BMI - LBKY001...
- Plot: BMI/Immun for LBKY001
- Plot: BMI/Immun for LBKY001+IHS006

Sample Scenario:

Researchers have questioned whether there is a relationship between a subject's vaccine response and their Body Mass Index.

Do subjects with a high BMI show a reduced immune response under a given vaccine protocol?

But first, a tour...

Active filters

subjects

SUBJECTS	477
es	3
cies	1
s & subtypes	7
STUDIES	6
y products	6
ASSAYS	4

LEARN ABOUT...


Studies Assays Study products

Search studies

- Home
- Learn about studies, assays, ..
- Find subjects
- Plot data
- View data grid

Description Start Date Products

ARIS 001
 Observational
 Study Goals:
 To determine fundamental character of the HIV virus and the mechanisms virus transmission.
 To determine the anti-HIV antibody

ARIS 008 
 Observational

ARIS 008 collects blood specimens from duration patients infected with HIV-1 to determine the frequency (and molecular mechanisms) of the antibody neutralization response, as well as the virus's mechanisms for antibody

IHS 006
 Phase I
 To assess the safety of an HIV DNA vaccine with or without administration of IL-45 DNA in a cohort of HIV negative adults.
 To evaluate the tolerability of IL-45 DNA (with escalating doses of 1 mg and 2.2 mg)

Apr 21st, 2007
 to Jul 18th, 2008
 14 months in duration

The "Learn About..." section of the CDS allows researchers to explore the data catalog from a variety of perspectives.

A researcher might start here to assess which studies might address a BMI/response relationship.

Active filters

subjects

SUBJECTS	477
es	3
cies	1
s & subtypes	7
STUDIES	6
study products	6
ASSAYS	4



Study: ARIS 008

[← back](#)[studies](#)

Select:

[all study subjects](#)[Home](#)[Learn about studies, assays, ..](#)[Find subjects](#)[Plot data](#)[View data grid](#)

Active filters

[All subjects](#)**SUBJECTS** **477**

sexes 3

species 1

races & subtypes 7

STUDIES **6**

study products 6

ASSAYS **4**

Network: ARIS

Study Type: Observational

Stage: Ongoing

First participant enrolled: Apr 12th, 2008

Follow up complete: Apr 12th, 2010

Description

ARIS 008 collects blood specimens from patients infected with HIV-1 to determine the frequency (and molecular mechanisms) of the antibody neutralization response, as well as the virus's mechanisms for antibody avoidance.

CDS editorial

The MIH has awarded a grant to ARIS to contribute to the Worldwide HIV/AIDS Vaccine Project (WWHVP). ARIS investigators will use state-of-the art technology and coordinated studies to address projects targeted at the production of a HIV-1 vaccine. In ARIS 008, investigators will explore the molecular basis of HIV-1 neutralization.

Study objectives

Primary Objectives:

- To determine the prevalence of acute HIV infection.

Contact information

[Contact the Collaborative DataSpace team](#) for more information[Propose an ancillary study](#)

Products

[VAC-HDNA022-VEC4](#)

Clinical Data

✓ = available in the Collaborative DataSpace

✓ Demographics

✓ Physical Exam

HIV Diagnostics

✓ = available in the Collaborative DataSpace

✓ HIV Test Results

✓ Lab Results

HIV Immunogenicity Assays

✓ = available in the Collaborative DataSpace

[NAb](#)

LEARN ABOUT...

Studies Assays  Study products

Description	Start Date	Products
<p>ARIS 001 Observational Study Goals: To determine fundamental characteristics of the HIV virus and the mechanisms of virus transmission. To determine the anti-HIV antibody</p>	<p>Apr 12th, 2008 to Apr 12th, 2010 23 months in duration</p>	
<p>ARIS 008 Observational ARIS 008 collects blood specimens from patients infected with HIV-1 to determine the frequency (and molecular mechanisms) of the antibody neutralization response, as well as the virus's mechanisms for antibody</p>	<p>Apr 12th, 2008 to Apr 12th, 2010 23 months in duration</p>	
<p>IHS 006 Phase I To assess the safety of an HIV DNA vaccine with or without administration of IL-45 DNA in a cohort of HIV negative adults. To evaluate the tolerability of IL-45 DNA (with escalating doses of 1 mg and 2.2 mg)</p>	<p>Apr 21st, 2007 to Jul 18th, 2008 14 months in duration</p>	

Home

Learn about studies, assays, ..

Find subjects

Plot data

View data grid

Active filters

All subjects

SUBJECTS 477

sexes 3

species 1

races & subtypes 7

STUDIES 6

study products 6

ASSAYS 4



LEARN ABOUT...

[Studies](#) [Assays](#) [Study products](#)

Name	Type	Platform/Target/Function
ADCC data	Cellular	Platform: ICS Target: Function: Activation
Luminex data	Humoral	Platform: Luminex Target: Function: Activation
mRNA assay	Humoral	Platform: ICS Target: Function: Inhibition

[Home](#)[Learn about studies, assays, ..](#)[Find subjects](#)[Plot data](#)[View data grid](#)

Active filters

All subjects

SUBJECTS 477

sexes 3

species 1

races & subtypes 7

STUDIES 6

study products 6

ASSAYS 4

LEARN ABOUT...

Studies Assays Study products

Product name	Type	Developer
Placebo Sugar placebo.	Sugar Class: Subclass:	MIAID/National Standard Lab/New Brook, Virginia

Plasmid IL-2 Adjuvant	Protein Class: Subclass:	Immunology Standards Institute, Meadowbrook, NC
--------------------------	--------------------------------	--

VAC-HDNA023-MPV VAC-HDNA023-MPV - Sa promotori SV40 Est usque ad placitum Research Institute ostendit Line magbilanggo ang Rous sarkoma Virus (SRV) tagataguyod fine superius salawikain magna. Nuper voce magna ulterius susceptor usum	Vaccine Class: DNA Subclass:	VRCenter/MNIIS, Athens, GA
--	------------------------------------	----------------------------

Home

Learn about studies, assays, ..

Find subjects

Plot data

View data grid

Active filters

All subjects

SUBJECTS 477

sexes 3

species 1

races & subtypes 7

STUDIES 6

study products 6

ASSAYS 4

FIND SUBJECTS...

by Subject characteristics

7 countries, 3 sexes, 3 hiv infection statuses, 1 species, 7 races & subtypes

477 subject characteristics

by Study products

6 study products

by Assays

by Studies

Home

Learn about studies, assays, ...

Find subjects

Plot data

View data grid

The “Find Subjects” view allows for the creation of virtual cohorts of subjects based on various criteria.

In our scenario, the researcher has used the Learn About pages to identify two studies that measured both BMI and Immune Response and wishes to investigate these subjects further.

ive filters

Subjects

SUBJECTS 477

s 3

es 1

s & subtypes 7


STUDIES 6

y products 6

ASSAYS 4

Subject characteristics

SORTED BY: RACE & SUBTYPE

Showing number of: **Subjects**[hide empty](#)[Home](#)[Learn about studies, assays, ...](#)[Find subjects](#)[Plot data](#)[View data grid](#)

Active filters

[All subjects](#)**SUBJECTS** 477

sexes 3

species 1

races & subtypes 7

STUDIES 6

study products 6

ASSAYS 4

Subject characteristics

SORTED BY: RACE & SUBTYPE

Subject characteristics


Study products

Assays

Studies

Showing number of: Subjects

hide empty



Home

Learn about studies, assays, ...

Find subjects

Plot data

View data grid

Active filters

All subjects

SUBJECTS 477

sexes 3

species 1

races & subtypes 7

STUDIES 6

study products 6

ASSAYS 4

Studies

SORTED BY: NAME

Showing number of: **Subjects**[hide empty](#)**ARIS 001****ARIS 008****DataSpaceProject****IHS 006****219****LBKY 001****223****LBKY 144****LBKY 244**[Home](#)[Learn about studies, assays, ...](#)[Find subjects](#)[Plot data](#)[View data grid](#)

Active filters

[All subjects](#)**SUBJECTS** **477**

sexes 3

species 1

races & subtypes 7

STUDIES **6**

study products 6

ASSAYS **4**



Studies

SORTED BY: NAME

Showing number of: **Subjects**[hide empty](#)

ARIS 001	
ARIS 008	
DataSpaceProject	
IHS 006	219
LBKY 001	223
LBKY 144	
LBKY 244	

[Home](#)[Learn about studies, assays, ...](#)[Find subjects](#)[Plot data](#)[View data grid](#)

Active filters

[All subjects](#)

CURRENT SELECTION

 StudyOR [use as filter](#)[label as subgroup](#)[clear](#)**SUBJECTS** 442 of 477

sexes 3 of 3

species 1 of 1

races & subtypes 7 of 7

STUDIES 2 of 6

study products 3 of 6

ASSAYS 2 of 4



Studies

SORTED BY: NAME

Showing number of: **Subjects**[hide empty](#)**ARIS 001****ARIS 008****DataSpaceProject****IHS 006****219****LBKY 001****223****LBKY 144****LBKY 244**[Home](#)[Learn about studies, assays, ...](#)[Find subjects](#)[Plot data](#)[View data grid](#)**Active filters**[save](#)[clear](#)

Study

LBKY 001

IHS 006

SUBJECTS **442**

sexes 3

species 1

races & subtypes 7

STUDIES **2**

study products 3

ASSAYS **2**

y = color =

Home

Learn about studies, assays, ...

Find subjects

Plot data

View data grid

Choose a "y"
Make selecti
Use subgroup

The "plot data" view allows researchers to explore data relationships between measures for the virtual cohort defined by the active filters.

In this case, the researcher will quickly plot the participants' BMI at enrollment against measured Immune Response at all time points.

Active filters

by

SUBJECTS 442

S 3

es 1

s & subtypes 7

STUDIES 2

study products 3

ASSAYS 2

antigens 20

labs 2

X =

CHOOSE A VARIABLE FOR THE Y AXIS...

Source

Demographics
HIV Test Results
Lab Results
Luminex
MRNA
NAb
Physical Exam

Variables

CD4
Hemoglobin
Immune Response
Lymphocytes

Definition: Immune Response

Scale:


Log Linear

set y axis


cancel

X = choose variable



y = Lab Results
Immune Response 

color =



X =

Home

Learn about studies, assays, ...

Find subjects

Plot data

View data grid

Active filters

In the plot: Immune Response

Study

SUBJECTS 233

sexes 3

species 1

racess & subtypes 7

STUDIES 2

study products 3

ASSAYS 2

antigens 20

labs 2

CHOOSE A VARIABLE FOR THE X AXIS...

Source

Time points
User groups

DATASETS
ADCC

Demographics
HIV Test Results
Lab Results
Luminex
MRNA

Definition: BMI at Enrollment

Scale:

Log Linear

Variables

Age at Enrollment
BMI at Enrollment
Baseline Ad5 Titer
Baseline Ad5 Titer Category
Baseline BMI Category
Circumcision Status
Comments
Country
Day of HIV Cutoff
EnrolledClinicalSite


set x axis

cancel

X = choose variable

y = Lab Results
Immune Response

color = choose variable



If the requested plot contains too many data points to display clearly or efficiently, the CDS will automatically switch to a “binned” plot, similar to a heat map.

Filtering the data further will show actual data points. For example, the researcher may wish to narrow the cohort to subjects who received selected vaccine products.

Home
Learn about studies, assays, ...
Find subjects
Plot data
View data grid

Active filters [save](#) [clear](#)

the plot: BMI at Enrollment, Immu

dy

LBKY 001
IHS 006


SUBJECTS 442
S 3
es 1
& subtypes 7

STUDIES 2
study products 3


ASSAYS 2
antigens 20
labs 2


X = Demographics
BMI at Enrollment



y = Lab Results
Immune Response 

color = [choose variable](#)



X = Demographics
BMI at Enrollment 

Home

Learn about studies, assays, ...

Find subjects


Plot data

View data grid

Active filters [save](#) [clear](#)

In the plot: BMI at Enrollment, Immu

Study

OR  LBKY 001
IHS 006

SUBJECTS 442

sexes 3

species 1

racess & subtypes 7

STUDIES 2

study products 3

ASSAYS 2

antigens 20


labs 2



y = Lab Results
Immune Response



color = choose variable



x = Demographics
BMI at Enrollment



Home

Learn about studies, assays, ...

Find subjects

Plot data

View data grid

Study products

SORTED BY: NAME

Subjects can fall into multiple Types.

- Subjects related to any (OR)
 Subjects related to all (AND)

All

HAS DATA IN CURRENT SELECTION

- Placebo
 VAC-HDNA022-VEC4
 VAC-HDNA023-MPV

NO DATA IN CURRENT SELECTION


- HIVAX-TPL12
 Plasmid IL-2
 VAC-HDNA019-CAP

filter

cancel

y = Lab Results
Immune Response

color = choose variable



x = Demographics
BMI at Enrollment

Home
 Learn about studies, assays, ...
 Find subjects
Plot data
 View data grid

Active filters [save](#) [clear](#)

In the plot: BMI at Enrollment, Im

Study

 LBKY 001
 IHS 006

Subjects given study product


 VAC-HDNA022-VEC4
 VAC-HDNA023-MPV
 HIVAX-TPL12
 Plasmid IL-2
 VAC-HDNA019-CAP

SUBJECTS 330
 sexes 3
 species 1
 races & subtypes 7

STUDIES 2
 study products 2

y = Lab Results
Immune Response

color = choose variable

X = Demographics
BMI at Enrollment

Home

Learn about studies, assays, ...

Find subjects

Plot data

View data grid

VAC-HDNA022-VEC4
 VAC-HDNA023-MPV
 HIVAX-TPL12
 Plasmid IL-2
 VAC-HDNA019-CAP

CURRENT SELECTION

● Subjects with:

BMI at Enrollment: ≥ 36.58 , <

use as filter

label as subgroup

clear

SUBJECTS 26 of 330

sexes 3 of 3

species 1 of 1

races & subtypes 5 of 7

STUDIES 2 of 2

study products 3 of 3


ASSAYS 2 of 2

antigens 20 of 20

labs 2 of 2

y = Lab Results
Immune Response

color = choose variable



x = Demographics
BMI at Enrollment

- Home
- Learn about studies, assays, ...
- Find subjects
- Plot data**
- View data grid

Active filters save clear

In the plot: BMI at Enrollment, Im

Study

OR ▾

- LBKY 001
- IHS 006

Subjects given study product

OR ▾

- VAC-HDNA022-VEC4
- VAC-HDNA023-MPV
- HIVAX-TPL12
- Plasmid IL-2
- VAC-HDNA019-CAP

SUBJECTS	330
sexes	3
species	1
racess & subtypes	7

STUDIES	2
study products	0

CHOOSE A VARIABLE FOR THE X AXIS...

Source

Time points
User groups

DATASETS
ADCC

Demographics

HIV Test Results

Lab Results

Luminex

MRNA

Definition: Baseline BMI Category

Variables

Age at Enrollment
BMI at Enrollment
Baseline Ad5 Titer
Baseline Ad5 Titer Category
Baseline BMI Category
Circumcision Status
Comments
Country
Day of HIV Cutoff
EnrolledClinicalSite

remove var

set x axis

cancel


X = Demographics
BMI at Enrollment

330
3
1
7
races & subtypes

STUDIES 2
study products

y = Lab Results
Immune Response

color = choose variable



x = Demographics
Baseline BMI Category

- Home
- Learn about studies, assays, ...
- Find subjects
- Plot data**
- View data grid

Active filters [save](#) [clear](#)

the plot: Baseline BMI Category

Study

R ▾

LBKY 001
IHS 006

Subjects given study product

R ▾

VAC-HDNA022-VEC4
VAC-HDNA023-MPV
HIVAX-TPL12
Plasmid IL-2
VAC-HDNA019-CAP

SUBJECTS 330
sexes 3
species 1
races & subtypes 7

STUDIES 2
study products 2

CHOOSE A COLOR VARIABLE...

Source

ADCC
Demographics
HIV Test Results
Lab Results
Luminex
MRNA
NAb
Physical Exam

Variables

Baseline BMI Category
Circumcision Status
Comments
Country
EnrolledClinicalSite
Group
HIV Infection Status
Prime Product and Schedule
Protocol Code
Protocol Completion

Definition: Country

set color variable

cancel


X = Demographics
Baseline BMI Category

races & subtypes 7

STUDIES 2

y = Lab Results Immune Response

color = Demographics: Country



- Home
- Learn about studies, assays, ...
- Find subjects
- Plot data**
- View data grid

Active filters save clear

In the plot: Baseline BMI Category

Study

OR

LBKY 001
IHS 006

Subjects given study product

OR

VAC-HDNA022-VEC4
VAC-HDNA023-MPV
HIVAX-TPL12
Plasmid IL-2
VAC-HDNA019-CAP

SUBJECTS 330
sexes 3
species 1
races & subtypes 7

STUDIES 2
study products 2

x = Demographics Baseline BMI Category

VIEW DATA GRID

export

options

choose from 121 columns

Home

Learn about studies, assays, ...

Find subjects

Plot data

View data grid

Study and time		Plot Data Results				
Subject ID	Study	Visit	Baseline	BMI	Country	Immune Response
276542	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006					
272626	IHS 006	Day 744	Underweight	USA		0.06
272626	IHS 006	Day 548	Underweight	USA		0.15
272626	IHS 006	Day 772	Underweight	USA		0.18
272626	IHS 006	Day 240	Underweight	USA		
272626	IHS 006	Day 492	Underweight	USA		0.05

The Data Grid view allows the researcher to view, sort, and filter data rows, as well as add additional columns.

This dataset will be exported to analyze the BMI/Immune Response relationship in more depth using external statistical tools.

Finally, this subject group will be saved in the CDS for future analysis.

Active filter

save

clear

the plot: Baseline BMI Category

Study

R

LBKY 001
IHS 006

Subjects given study product

R

VAC-HDNA023-MPV
HIVAX-TPL12
Plasmid IL-2
VAC-HDNA019-CAP
VAC-HDNA022-VEC4

SUBJECTS 330
sexes 3
species 1
races & subtypes 7

VIEW DATA GRID

export

citations

choose from 121 columns

Study and time			Plot Data Results			
Subject ID	Study	Visit	Baseline Category	BMI	Country	Immune Response
276542	IHS 006	Day 0	Underweight		Germany	
272626	IHS 006	Day 716	Underweight		USA	0.04
272626	IHS 006	Day 884	Underweight		USA	0.16
272626	IHS 006	Day 912	Underweight		USA	0.12
272626	IHS 006	Day 380	Underweight		USA	0.10
272626	IHS 006	Day 660	Underweight		USA	0.07
272626	IHS 006	Day 352	Underweight		USA	0.10
272626	IHS 006	Day 464	Underweight		USA	0.06
272626	IHS 006	Day 520	Underweight		USA	0.10
272626	IHS 006	Day 688	Underweight		USA	0.04
272626	IHS 006	Day 968	Underweight		USA	0.09
272626	IHS 006	Day 604	Underweight		USA	0.09
272626	IHS 006	Day 632	Underweight		USA	0.07
272626	IHS 006	Day 940	Underweight		USA	0.08
272626	IHS 006	Day 828	Underweight		USA	0.13
272626	IHS 006	Day 744	Underweight		USA	0.06
272626	IHS 006	Day 548	Underweight		USA	0.15
272626	IHS 006	Day 772	Underweight		USA	0.18
272626	IHS 006	Day 240	Underweight		USA	
272626	IHS 006	Day 492	Underweight		USA	0.05

Save group

⚠ Current Selection will be applied

BMI/Immune Response Hypothesis

Non-placebo subjects from LBKY 001/IHS 006; observed lower response in Obese subjects, significance and causal relationship unclear.

- Live: Update group with new data
 Snapshot: Keep this group static

Or...

[replace an existing group](#)

save

cancel

The Other (Often Unappreciated) Components of the CDS Program

Important work
is hidden
beneath the
surface



CDS application

Data harmonization/integration


Data annotation

User services

Outreach, training, support


Program and data governance

Integrated CDS Program



Integrated CDS Program

Why are these other
components
important?



CDS Program: Data Component

Main Elements

- Study Catalog – Facilitate discovery and provide historical context
- Integrated Data – High volume of combined data
- Annotation – Critical to interpretation

Other Considerations

- Whether to restrict users to combine certain data
- CDS data model, data harmonization, controlled terminology
- Raw versus processed data



CDS Program: Services Component

Main Elements

- Outreach – Promote utilization and build community
- Analysis – Assist with analyses and interpretation
- Support – Combination of self-service and facilitated support

Other Considerations

- Maintaining accurate and current list of users
- User metrics



CDS Program: Governance Component

Main Elements

- Collaboration – Network engagement in governance
- Data Sharing – Global data sharing and use agreements
- Harmonization – Increase efficiency of data integration

Other Considerations

- Public access
- Flexible data sharing and collaboration levels
- Identify potential legal issues and informed consent concerns




COLLABORATIVE DATASPACE PROGRAM **APPROACH**



Current process




CDS process



Future of CDS

CDS Program Extensibility



Readily applicable to other pathogen/vaccine problems

Possibly or partially applicable

HIV-specific

COLLABORATIVE DATASPACE PROGRAM **ACKNOWLEDGEMENTS**



Oversight, coordination,
data integration



Product design




Product development



Consultation on data
integration and system
development

Questions?

Appendix




COMPLEMENTARY PLATFORMS

CDS

- Population-oriented exploration of clinical and pre-clinical CAVD, AVEG, HVTN data, areas of study
- Data, statistical, outreach and user support services

ImmuneSpace

- Analytic front-end over integrated ImmPort data, including rich tools for specialized analyses
- Systems biology approach to high-dimensional/high-throughput data; e.g., gene expression



Atlas

- Operations-oriented portal for SCHARP networks focused on data acquisition
- Study and dataset-based sharing with light analytics

ImmPort

- Repository for data generated and submitted by NIAID/DAIT investigators
- Focus on data standardization and curation, with a handful of analytic tools for selected data types

